The research on PD-L1 and its receptor PD-1 have revolutionized the treatment of this disease stage, enabling us to offer somewhat effective therapeutic options to patients with advanced and metastatic cSCC that is ineligible for local curative approaches (surgery and/or radiotherapy). The gene discussed is PDCD1; the disease is skin squamous cell carcinoma.